
Andrew Ip

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7399190/publications.pdf Version: 2024-02-01



ΔΝΟΡΕΥΝΙΟ

#	Article	IF	CITATIONS
1	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatology, The, 2020, 2, e603-e612.	2.2	228
2	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study. PLoS ONE, 2020, 15, e0237693.	1.1	110
3	Clinical Integration of Digital Solutions in Health Care: An Overview of the Current Landscape of Digital Technologies in Cancer Care. JCO Clinical Cancer Informatics, 2018, 2, 1-9.	1.0	92
4	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Oncologist, 2016, 21, 178-187.	1.9	47
5	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. BMC Infectious Diseases, 2021, 21, 72.	1.3	39
6	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. JCI Insight, 2021, 6, .	2.3	29
7	A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Advances, 2022, 6, 2757-2762.	2.5	19
8	The association of physical activity before and after lymphoma diagnosis with survival outcomes. American Journal of Hematology, 2018, 93, 1543-1550.	2.0	16
9	COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. PLoS ONE, 2021, 16, e0248128.	1.1	9
10	Induction Therapy in Localized Pancreatic Cancer. Pancreas, 2019, 48, 913-919.	0.5	7
11	Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19. PLoS ONE, 2021, 16, e0255228.	1.1	7
12	Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood, 2021, 138, 165-165.	0.6	6
13	Clotting events among hospitalized patients infected with COVID-19 in a large multisite cohort in the United States. PLoS ONE, 2022, 17, e0262352.	1.1	6
14	Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications. Journal of Clinical Oncology, 2020, 38, 1367-1368.	0.8	4
15	COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study. Blood, 2020, 136, 6-7.	0.6	4
16	Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation. JAMA Network Open, 2022, 5, e223687.	2.8	4
17	A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy. Blood, 2021, 138, 2495-2495.	0.6	1
18	Cell-free RNA in liquid biopsy and biomarkers profiling of hematologic and solid tumors Journal of Clinical Oncology, 2022, 40, 3047-3047.	0.8	1

Andrew Ip

#	Article	IF	CITATIONS
19	Late immune-related adverse events with immune checkpoint inhibitors Journal of Clinical Oncology, 2021, 39, 2635-2635.	0.8	0
20	Real-world outcomes of treatment with immune checkpoint inhibitors in unique patient cohorts: Elderly, non-caucasian race, poor performance status, obese, chronic viral infections, and autoimmune diseases Journal of Clinical Oncology, 2021, 39, 2641-2641.	0.8	0
21	Higher Incidence of Germline Mutations in DNA Damage Response Genes in Lymphoid Than in Myeloid Neoplasms without Significant Increase in the Prevalence of Clonal Hematopoiesis. Blood, 2020, 136, 4-5.	0.6	0
22	Assessing effectiveness of first-line carboplatin, pemetrexed, and pembrolizumab in patients with recurrent/metastatic lung adenocarcinoma Journal of Clinical Oncology, 2022, 40, e21045-e21045.	0.8	0
23	Differential diagnosis of hematologic and solid tumors using targeted transcriptome and artificial intelligence Journal of Clinical Oncology, 2022, 40, 3018-3018.	0.8	0
24	Combining cell-free RNA (cfRNA) with cell-free total nucleic acid (cfTNA) as a new paradigm for liquid biopsy Journal of Clinical Oncology, 2022, 40, 3048-3048.	0.8	0